Tag Archives: GlaxoSmithKline

Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.

Posted on May 18, 2012 by Barbara Arzymanow

The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading →

Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology | Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing | Leave a comment

	Lali Sekhon, MD on Tackling obesity – What the UK…
	Author Ingrid Hall on Ovarian Cancer – Make wo…
	David Bradley on 2020health comments on GMC rep…
	20 things to make yo… on Equal treatment for Depression…
	David Bradley on Guest Blogspot: Misleading, Bi…

Tag Archives: GlaxoSmithKline

Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.

TwentyTwentyTweets

Email Subscription

Recent Posts

Pages

Opinions

Categories